Literature DB >> 34099819

Design, synthesis, molecular docking, and in vitro α-glucosidase inhibitory activities of novel 3-amino-2,4-diarylbenzo[4,5]imidazo[1,2-a]pyrimidines against yeast and rat α-glucosidase.

Fariba Peytam1, Ghazaleh Takalloobanafshi2, Toktam Saadattalab3, Maryam Norouzbahari4, Zahra Emamgholipour3, Setareh Moghimi1, Loghman Firoozpour1, Hamid Reza Bijanzadeh5, Mohammad Ali Faramarzi6, Somayeh Mojtabavi6, Parviz Rashidi-Ranjbar2, Saeed Karima7, Roya Pakraad7, Alireza Foroumadi8,9.   

Abstract

In an attempt to find novel, potent α-glucosidase inhibitors, a library of poly-substituted 3-amino-2,4-diarylbenzo[4,5]imidazo[1,2-a]pyrimidines 3a-ag have been synthesized through heating a mixture of 2-aminobenzimidazoles 1 and α-azidochalcone 2 under the mild conditions. This efficient, facile protocol has been resulted into the desirable compounds with a wide substrate scope in good to excellent yields. Afterwards, their inhibitory activities against yeast α-glucosidase enzyme were investigated. Showing IC50 values ranging from 16.4 ± 0.36 µM to 297.0 ± 1.2 µM confirmed their excellent potency to inhibit α-glucosidase which encouraged us to perform further studies on α-glucosidase enzymes obtained from rat as a mammal source. Among various synthesized 3-amino-2,4-diarylbenzo[4,5]imidazo[1,2-a]pyrimidines, compound 3k exhibited the highest potency against both Saccharomyces cerevisiae α-glucosidase (IC50 = 16.4 ± 0.36 μM) and rat small intestine α-glucosidase (IC50 = 45.0 ± 8.2 μM). Moreover, the role of amine moiety on the observed activity was studied through substituting with chlorine and hydrogen resulted into a considerable deterioration on the inhibitory activity. Kinetic study and molecular docking study have confirmed the in-vitro results.

Entities:  

Year:  2021        PMID: 34099819     DOI: 10.1038/s41598-021-91473-z

Source DB:  PubMed          Journal:  Sci Rep        ISSN: 2045-2322            Impact factor:   4.379


  40 in total

1.  Advantages of alpha-glucosidase inhibition as monotherapy in elderly type 2 diabetic patients.

Authors:  P S Johnston; H E Lebovitz; R F Coniff; D C Simonson; P Raskin; C L Munera
Journal:  J Clin Endocrinol Metab       Date:  1998-05       Impact factor: 5.958

Review 2.  Synthetic heterocyclic candidates as promising α-glucosidase inhibitors: An overview.

Authors:  Manoj Dhameja; Preeti Gupta
Journal:  Eur J Med Chem       Date:  2019-04-30       Impact factor: 6.514

3.  alpha-Glucosidase inhibitors prevent diet-induced increases in intestinal sugar transport in diabetic mice.

Authors:  Donatella M Casirola; Ronaldo P Ferraris
Journal:  Metabolism       Date:  2006-06       Impact factor: 8.694

Review 4.  Current anti-diabetic agents and their molecular targets: A review.

Authors:  Nagaraju Kerru; Ashona Singh-Pillay; Paul Awolade; Parvesh Singh
Journal:  Eur J Med Chem       Date:  2018-05-03       Impact factor: 6.514

5.  Synthesis of some novel heterocylic compounds derived from 2-[3-(4-chlorophenyl)-5-(4-methoxybenzyl)-4H-1,2,4-triazol-4-yl]acetohydrazide and investigation of their lipase and α-glucosidase inhibition.

Authors:  Olcay Bekircan; Serdar Ülker; Emre Menteşe
Journal:  J Enzyme Inhib Med Chem       Date:  2015-02-02       Impact factor: 5.051

6.  Novel synthesis of dihydropyrimidines for α-glucosidase inhibition to treat type 2 diabetes: in vitro biological evaluation and in silico docking.

Authors:  Muhammad Yar; Marek Bajda; Lubna Shahzadi; Sohail Anjum Shahzad; Maqsood Ahmed; Muhammad Ashraf; Umber Alam; Islam Ullah Khan; Ather Farooq Khan
Journal:  Bioorg Chem       Date:  2014-05-15       Impact factor: 5.275

7.  Kidney disease and related findings in the diabetes control and complications trial/epidemiology of diabetes interventions and complications study.

Authors:  Ian H de Boer
Journal:  Diabetes Care       Date:  2014       Impact factor: 19.112

8.  Synergisms in Alpha-glucosidase Inhibition and Antioxidant Activity of Camellia sinensis L. Kuntze and Eugenia uniflora L. Ethanolic Extracts.

Authors:  Juliana Vinholes; Márcia Vizzotto
Journal:  Pharmacognosy Res       Date:  2017 Jan-Mar

9.  Endogenous advanced glycation end products in pancreatic islets after short-term carbohydrate intervention in obese, diabetes-prone mice.

Authors:  Richard Kehm; Jana Rückriemen; Daniela Weber; Stefanie Deubel; Tilman Grune; Annika Höhn
Journal:  Nutr Diabetes       Date:  2019-03-11       Impact factor: 5.097

Review 10.  Alpha-glucosidase inhibitors in the early treatment of type 2 diabetes.

Authors:  Floris Alexander van de Laar
Journal:  Vasc Health Risk Manag       Date:  2008
View more
  3 in total

1.  Inhibition of α-Glucosidase, Acetylcholinesterase, and Nitric Oxide Production by Phytochemicals Isolated from Millettia speciosa-In Vitro and Molecular Docking Studies.

Authors:  Nguyen Ngoc Tuan; Huong Nguyen Thi; Chau Le Thi My; Tang Xuan Hai; Hieu Tran Trung; Anh Nguyen Thi Kim; Thanh Nguyen Tan; Tan Le Van; Cuong Quoc Nguyen; Quang De Tran; Ping-Chung Kuo; Quang Le Dang; Tran Dinh Thang
Journal:  Plants (Basel)       Date:  2022-01-30

2.  Dihydropyrimidinones Against Multiresistant Bacteria.

Authors:  Marisa Castro Jara; Allison Carlos Assunção Silva; Marina Ritter; Adriana Fernandes da Silva; Carolina Lambrecht Gonçalves; Pedro Rassier Dos Santos; Luciano Sisconetto Borja; Cláudio Martin Pereira de Pereira; Patrícia da Silva Nascente
Journal:  Front Microbiol       Date:  2022-03-18       Impact factor: 5.640

3.  Discovery of Novel Coumarin Derivatives as Potential Dual Inhibitors against α-Glucosidase and α-Amylase for the Management of Post-Prandial Hyperglycemia via Molecular Modelling Approaches.

Authors:  Shashank M Patil; Reshma Mary Martiz; A M Satish; Abdullah M Shbeer; Mohammed Ageel; Mohammed Al-Ghorbani; Lakshmi Ranganatha; Saravanan Parameswaran; Ramith Ramu
Journal:  Molecules       Date:  2022-06-17       Impact factor: 4.927

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.